A review of Chinese heart transplantation literature in 2024
10.12464/j.issn.1674-7445.2025131
- VernacularTitle:2024年中国心脏移植文献盘点
- Author:
Jiade ZHU
1
;
Min WU
1
Author Information
1. Department of Cardiac Surgery, Guangdong Provincial Institute of Cardiovascular Disease, Guangdong Provincial People's Hospital Affiliated to Southern Medical University, Guangzhou 510080, China.
- Publication Type:AcademicSummary
- Keywords:
Heart transplantation;
Rejection;
End-stage heart failure;
Dendritic cell;
Ischemia-reperfusion injury;
Risk factor;
Regulatory T cell;
Imaging technique
- From:
Organ Transplantation
2025;16(3):368-378
- CountryChina
- Language:Chinese
-
Abstract:
Heart transplantation is the gold standard for the treatment of end-stage heart failure. For patients with end-stage heart failure, there are still clinical issues such as unclear methods for right ventricular function assessment, and overly general clinical prognosis and risk stratification. For end-stage heart failure patients who have undergone heart transplantation, they still face a series of challenges after surgery, such as acute kidney injury, rejection, infection and long-term graft dysfunction, and graft vascular disease, etc. In recent years, with the progress of cardiac imaging assessment, especially cardiac MRI technology, and the development of basic research work on post-transplant rejection and immune tolerance in heart transplantation, Chinese researchers have focused on solving these problems in the field of heart transplantation and have achieved remarkable results. This article will systematically review the academic achievements of Chinese researchers in the field of heart transplantation in 2024, including clinical and basic research, as well as the application of new technologies and innovative clinical scoring systems, to provide new ideas and strategies for solving major problems in the field of heart transplantation and to promote the development of Chinese heart transplantation to a higher level.
